BrightGene Bio-Medical Hits Day High with 9.05% Surge in Stock Price

BrightGene Bio-Medical Technology Co., Ltd. has experienced a significant surge in its stock price, gaining 9.05% on March 18, 2026. The stock reached an intraday high of CNY 51.60, showcasing notable activity in the pharmaceuticals and biotechnology sector. In terms of performance metrics, BrightGene has outperformed the China Shanghai Composite index, which recorded a modest gain of 0.32% on the same day. Over the past week, the company’s stock has risen by 20.09%, while its one-month performance stands at 13.26%. Year-to-date, BrightGene has achieved a 4.67% increase, and its one-year performance is impressive at 24.33%, compared to the Shanghai Composite's 18.46%. Despite these gains, the company faces challenges, including a high debt-to-equity ratio and declining profitability indicators. The return on equity is relatively low at 1.27%, and the price-to-earnings ratio is notably high at 386.00. These factors contribute to a complex financial landscape for BrightGene, even as it celebrates a strong day in the market.